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Abstract
Background—Maternal vitamin D status has been associated with lower bone mass of the 
offspring in many, but not all, observational studies. However, proof that maternal vitamin D 
repletion during pregnancy improves offspring bone mass is lacking.
Methods—Between 06/10/2008 and 11/02/2014, we randomly assigned pregnant women with a 
serum 25-hydroxyvitamin D [25(OH)D] 25-100nmol/l at 12 weeks’  gestation to either 1000IU/day 
cholecalciferol or matched placebo from 14 weeks’  gestation until delivery. Serum 25(OH)D was 
measured at 14 and 34 weeks’  gestation. Neonatal whole body bone mineral, assessed within 2 
weeks after birth (n=665) by dual-energy X-ray absorptiometry (DXA), was the primary outcome. 
Secondary pre-specified analyses explored interactions with study centre, maternal ethnicity, 
parity, compliance, protocol completion, baseline BMI, baseline 25(OH)D and change in 
25(OH)D from 14 to 34 weeks; and offspring sex and season of birth.
Findings—We found no difference in neonatal whole body bone mineral content (BMC) of 
infants born to mothers randomised to 1000IU/day cholecalciferol compared with infants born to 
mothers randomised to placebo [61.6g (95%CI: 60.3, 62.8g) vs 60.5g (95%CI: 59.3, 61.7g) 
respectively, p=0.21].
Interpretation—Supplementation of mothers with 1000IU/day cholecalciferol during pregnancy 
did not lead to increased offspring whole body BMC compared with placebo.
Keywords
Vitamin D; cholecalciferol; supplementation; trial; osteoporosis; epidemiology; DXA; pregnancy; 
neonate
BACKGROUND AND OBJECTIVES
Osteoporosis is a devastating disease and its high prevalence makes it eminently suitable for 
population-wide public health interventions aimed at optimising bone health.1 There is 
increasing evidence that early growth, and factors acting in utero or during early infancy, 
may influence the trajectory of long-term skeletal accrual to peak bone mass.1 In particular, 
maternal serum 25(OH)-vitamin D [25(OH)D] concentrations in pregnancy have been 
associated with offspring bone morphology2-5 and bone mass6,7 up to young adulthood.8 
The main determinant of 25(OH)D concentrations in most populations is UVB exposure to 
the skin, which varies markedly by season in temperate climes.9 Seasonal differences in 
neonatal BMC have been demonstrated,10,11 with effects potentially modified by vitamin D 
supplementation,11 and maternal UVB exposure during pregnancy has been positively 
associated with bone mass in childhood.6,12 However, not all studies have demonstrated a 
benefit of higher maternal 25(OH)D levels in pregnancy on childhood skeletal health.13-15 
Whole body bone mineral content (BMC) is the recommended measure of bone mass in 
children; although of limited clinical utility in neonate due to the lack of normative data,16 
infant DXA been widely used in research studies,17-20 where comparisons are internal. 
Childhood BMC is inversely related to childhood fracture risk,21; although data spanning 
from conception to peak bone mass in a single cohort are lacking, the current evidence-base 
supports tracking of bone mineral content over this time,22-25 and the magnitude of peak 
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bone mass achieved is an important determinant of future fracture risk.26 The aim of the 
present trial was therefore to test the hypothesis that neonates born to mothers supplemented 
with vitamin D during pregnancy would have greater whole body bone mineral content 
(BMC) at birth than those of mothers who had not received supplementation.27 Given the 
previously documented importance of season for both 25(OH)D concentrations and 
childhood bone mass, we further hypothesised that there would be an interaction between 
season of birth and treatment effect.
METHODS
Trial design
A detailed description of The Maternal Vitamin D Osteoporosis Study (MAVIDOS) has 
been previously published.27 Briefly, MAVIDOS is a multicentre, double-blind, randomised, 
placebo-controlled trial of vitamin D supplementation in pregnancy in the United Kingdom. 
The study was conducted in accordance with guidelines laid down in the Declaration of 
Helsinki and was approved by the Southampton and South West Hampshire Research Ethics 
Committee. MAVIDOS was registered prospectively (ISRCTN:82927713; EUDRACT:
2007-001716-23); full approval from UK MHRA was granted, and written, informed 
consent was obtained from all participants.
Participants
Pregnant women were recruited when attending for early pregnancy ultrasound screening at 
three study sites [University Hospital Southampton NHS Foundation Trust, Southampton, 
UK; Oxford University Hospitals NHS Trust, Oxford, UK; Sheffield Hospitals NHS Trust 
(University of Sheffield), Sheffield, UK] between 06/10/2008 and 11/02/2014. Inclusion 
criteria were: age over 18 years, singleton pregnancy, gestation less than 17 weeks based on 
last menstrual period (LMP) and ultrasound measurements, and aiming to give birth at the 
local maternity hospital. Women with known metabolic bone disease, renal stones, 
hyperparathyroidism or hypercalciuria, those with a diagnosis of cancer in the last 10 years, 
those unable to give informed consent or comply with the protocol, those taking medication 
known to interfere with fetal growth, those with fetal anomalies on ultrasonography and 
women already using >400IU/day vitamin D supplementation were excluded. A screening 
blood sample was obtained and analysed on the local NHS platforms and only 25 and 
100nmol/l and serum calcium<2.75mmol/l were eligible to enrol in the study. All three 
laboratories (Southampton, Oxford, Sheffield) were accredited by the Vitamin D External 
Quality Assessment Scheme (DEQAS) (http://www.deqas.org/).
Trial assessments
Questionnaire and anthropometry—All participants received standard antenatal care, 
and were able to continue self-administration of antenatal multivitamins containing up to 
400IU/day vitamin D. Women were assessed in detail at 14 and 34 weeks’  gestation 
including assessments of diet (including calcium and vitamin D intake), smoking, alcohol 
consumption, health, physical activity, medications, supplements (all interviewer-led 
questionnaires) and anthropometry.27 Anthropometric measurements of the newborns were 
obtained, and information on obstetric complications was extracted from maternity records.
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Biochemical—Study blood samples were collected from the mother at 14 and 34 weeks’  
gestation, and stored at −80°C after processing. Measurement of plasma 25(OH)D (Liaison 
RIA automated platform, Diasorin, Minnesota, USA), calcium, alkaline phosphatase, and 
albumin was undertaken centrally (MRC Human Nutrition Research, Cambridge, UK) in a 
single batch at the end of the study. Measurement of vitamin D binding protein is ongoing. 
Details of assay performance and quality control through participation in DEQAS, NIST and 
NEQAS are given elsewhere.28,29
DXA—The baby underwent DXA assessment at whole body and lumbar spine sites 
[Hologic Discovery (Hologic Inc., Bedford, MA, USA) or GE-Lunar iDXA (GE-Lunar, 
Madison, Wisconsin, US) with neonatal software] within 2 weeks after birth. In order to 
maximise scan quality, the infant was undressed, and clothed in a standard towel, fed and 
pacified before the assessment. Each instrument underwent daily QC, with cross-calibration 
between sites. The total radiation dose was estimated as 0.04mSv, equivalent to 
approximately 7 days’  exposure to background radiation in the UK. All DXA images were 
reviewed by two operators for movement artefacts and quality.
Interventions, randomisation and blinding—Women were randomised at 14 weeks’  
gestation (or as soon as possible before 17 weeks’  gestation if recruited later) to either 
cholecalciferol 1000IU/day or matched placebo [Merck KGaA, (Darmstadt, Germany)/ 
Sharp Clinical Services (Crickhowell, UK; previously DHP-Bilcare)]. Packs were 
randomised in a 1:1 ratio in randomly permuted blocks of 10, starting randomly midway 
through the block, and sequentially numbered, by Sharp Clinical Services Ltd prior to 
delivery to the study sites, and then dispensed in order by each study pharmacist. Each pack 
contained sufficient capsules for the study duration and both the participant and research 
team were blind to treatment allocation throughout the study duration.
Outcomes
The primary outcome was whole body BMC of the neonate. Although we had originally 
planned to use whole body BMC adjusted for age, it was judged following further statistical 
review, in this randomised controlled trial setting, appropriate to include offspring age in a 
sensitivity analysis, rather than as the primary outcome. Secondary outcomes included 
maternal 25(OH)D concentration at 34 weeks’  gestation; change in 25(OH)D between 14 
and 34 weeks’  gestation, neonatal whole body bone area and bone mineral density, and 
neonatal bone indices at the spine. In order to preserve statistical power, rather than perform 
separate analyses (as planned in original protocol) for those who completed the protocol, 
complied with treatment, demonstrated a rise in 25(OH)D, and stratification by baseline 
25(OH)D, we explored these potential effect modifiers via their incorporation as interaction 
terms in regression models (described below). Safety analyses examined the frequency of 
adverse outcomes including: infection, nausea/vomiting, diarrhoea, abdominal pain, 
headache, hypertension, hypercalcaemia (greater than equal to 2.75mmol/l) at 34 weeks’  
gestation, intrauterine growth restriction (IUGR), preterm birth (less than 37 weeks’  
gestation), instrumental delivery, severe postpartum haemorrhage, stillbirth or neonatal 
death, congenital abnormalities.
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Sample size
We estimated the sample size using the results from the Princess Anne Hospital Study,6 in 
which a difference of 0.42SD in whole body BMC was found between the infants of mothers 
who had been vitamin D deficient and those of mothers who had been vitamin D replete 
during pregnancy. Given this single observational study, we powered the trial conservatively, 
calculating that to detect 50% of this difference in whole body BMC at birth between the 
neonates of mothers who were deficient in vitamin D versus those replete in pregnancy 
(0.21SD or 3.5g), at the 5% significance level with 90% power, would require recruitment of 
477 neonates in each arm.
Statistical analysis
We undertook analyses on an intention to treat (ITT) basis for all those with a neonatal DXA 
assessment; the analysis plan was published prior to unblinding of the study.27 At the request 
of the Data Monitoring Committee, an interim safety analysis of serum calcium 
concentration was requested after two years of recruitment, but no analysis of DXA 
outcomes was undertaken until follow-up of all participants had been completed. All data 
were checked for normality by visual inspection of histograms. Data were assumed to be 
missing at random. Comparison was made between treatment groups using Student t-test 
and Mann-Witney U test for normally and non-normally distributed outcomes respectively. 
Categorical outcomes were compared using ů2 test. DXA indices included neonatal whole 
body bone area, bone mineral content, bone mineral density, lean and fat. In order to assess 
bone mass independent of body size, we used bone mineral content adjusted for birth length 
in a regression model. Given the seasonal change in the 25(OH)-vitamin D observed in 
many previous studies, we hypothesised, a priori, that there might be an interaction between 
treatment and season of birth. We defined season of birth using the UK Meteorological 
Office classification, as winter (December-February), spring (March-May), summer (June-
August) and autumn (September-November) [www.metoffice.gov.uk], and secondly 
explored differences in treatment effect by individual month of birth. We also investigated 
pre-specified interactions between treatment and offspring sex, and between treatment and 
ethnicity, as both these factors have been associated with variations in vitamin D 
metabolism. Since there is clear evidence of differences in body composition between first 
and subsequent offspring1, and an inverse relationship between body mass index and 
25(OH)D concentration, we hypothesised interactions between each of these 2 variables and 
treatment. Finally we reasoned that treatment might be more effective in those who fully 
complied with the protocol and were compliant with medication, who had low 
concentrations of 25(OH)D at baseline, or in those with a greater change in 25(OH)D from 
14 to 34 weeks, and that for a combination of reasons given above, there might be 
differences by study centre, providing the basis for the final 5 interaction analyses. In 
summary, the interactions tested were with: study centre, maternal ethnicity, parity, 
compliance, protocol completion, baseline BMI, baseline 25(OH)D and change in 25(OH)D 
from 14 to 34 weeks; and offspring sex and season of birth. All these interactions were 
explored in multivariable linear regression (with the independent variables, for example: 
treatment; season; treatment*season, and inclusion of no other covariates). In further 
analyses we adjusted bone outcomes for postnatal age at DXA. Given that the secondary 
analyses were pre-specified and hypothesis-based, and that the study was powered for the 
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primary outcome, it was not judged appropriate to undertake correction for multiple testing, 
recognising that any statistically significant results from the secondary analysis would 
require further confirmation in future studies. With 10 analyses and an alpha of 0.05, we 
calculated that the probably of observing one or more false positive associations was 40% 
[equal to (1-0.95^10)*100]. All analysis was performed by SD, SRC and HMI using Stata 
v13.1 (Statacorp, College Station, Texas, USA). A p value of <0.05 was accepted as 
statistically significant.
Role of the funding source
The study was funded by Arthritis Research UK, UK Medical Research Council, UK 
National Institute for Health Research, and the Bupa Foundation. The original protocol 
incorporated suggestions from the Arthritis Research UK Clinical Trials Collaboration. The 
funders had no other role in the study and the corresponding author had full access to all of 
the data and the final responsibility to submit for publication.
RESULTS
Participants
A total of 1449 women were initially eligible after screening and consented to a blood test to 
determine early pregnancy 25(OH)D status. Of these, 148 were ineligible to participate due 
to either 25(OH)D<25nmol/l (n=59) or 25(OH)D>100nmol/l (n=89). None had a plasma 
calcium >2.75 mmol/L. A further 167 women withdrew prior to randomisation. Thus, 1134 
were randomised (Figure 1), of whom 965 (85.1%) remained in the study until delivery. A 
total of 836 (73.7%) neonates had a DXA scan. After excluding scans with significant 
movement artefact, DXA scan data were available for 737 neonates (65.0%), comprising 
665 assessments at the whole body (intervention, n=338; placebo, n=327) and 628 at the 
lumbar spine (intervention, n=305; placebo, n=323), meaning that numbers were somewhat 
lower than specified in the original power calculation.
Maternal characteristics
Women in the treatment and placebo group at randomisation were of similar age, parity, 
educational attainment, smoking, exercise participation and ethnicity (Table 1). Height was 
also similar between the two groups, but weight, BMI and sum of skinfold thicknesses were 
greater in the placebo arm (Table 1). The women who remained in the trial until their baby 
was born were older (30.7 vs 28.9 years, p<0.001) and more likely to be white Caucasian 
(94.8% vs 89.2%, p=0.01), than those who withdrew. Women whose infants underwent 
DXA scanning tended to be older, and be less likely to smoke and have lower skinfold 
thicknesses (Supplementary Table 1), than women whose infants did not undergo DXA 
assessment.
Neonatal bone indices, anthropometry and body composition
There was no difference in neonatal whole body bone mineral content (BMC) of infants 
born to mothers randomised to 1000IU/day cholecalciferol compared with infants born to 
mothers randomised to placebo [61.6g (95%CI: 60.3, 62.8g) vs 60.5g (95%CI: 59.3, 61.7g) 
respectively, p=0.21]. Similarly, there was no difference in bone area, bone mineral density, 
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BMC adjusted for birth length, fat or lean mass of the neonate by treatment allocation (Table 
2 and Supplementary Figure 1). There was no significant difference in neonatal bone indices 
at the spine, or birth weight, length, head or abdominal circumference between the two 
treatment groups (Table 2).
Pre-specified secondary analyses
A priori, we hypothesized an interaction between treatment group and offspring season of 
birth.27 Supplementary Table 2 demonstrates the maternal baseline characteristics by 
treatment group and season of offspring delivery. The formal interaction term between 
treatment group and season of birth on offspring BMC was statistically significant (p=0.04) 
and the effect of treatment was of substantially greater magnitude [mean difference 5.5g 
(95%CI: 1.8, 9.1, p=0.004)] in winter months (December to February inclusive) than in the 
remaining seasons (Figure 2). A similar winter effect was observed for offspring whole body 
bone area (mean difference by group=11.5cm2, p=0.05), bone mineral density (mean 
difference by group=0.01g/cm2; p=0.04), bone mineral content adjusted for length (mean 
difference by group=3.7g, p=0.03) and indices of body composition (Supplementary Table 3 
and Supplementary Figure 3). Results were similar for each of the 3 winter months 
(Supplementary Table 4), albeit with the statistical significance limited by the reduced 
sample size when stratified by individual month of delivery. Results were little changed after 
bone indices were adjusted for postnatal age at DXA. There was no evidence of a treatment 
season interaction for offspring birth length (p=0.95) or birth weight (p=0.19). Further pre-
specified interactions for neonatal BMC between treatment and offspring sex (p=0.92); 
maternal BMI (p=0.91); maternal parity (p=0.95); recruitment centre (p=0.67); ethnicity 
(p=0.12); protocol completion (p=0.60); treatment compliance (p=0.70); baseline 25(OH)D 
status (p=0.67; Supplementary Table 5) and change in 25(OH)D (p=0.91) were not 
statistically significant. A further analysis of the effect of baseline 25(OH)D status on 
treatment efficacy within the winter group also demonstrated no statistically significant 
interaction (p=0.31).
Maternal 25(OH)D status
Baseline 25(OH)D status was similar in both groups (Table 1) and varied by season 
(Supplementary Table 6 and Supplementary Figure 4). Maternal 25(OH)D at 34 weeks’  
gestation was significantly higher in the women who received 1000IU/day 
(68.2±21.9nmol/l) compared with placebo (43.4±22.4nmol/l), p<0.001. The percentage of 
participants with insufficient 25(OH)D (<50nmol/l) was similar at baseline (Table 1), but 
significantly lower at 34 weeks’  gestation in the intervention compared with placebo group 
(16.6% vs 63.5%, p<0.001). Furthermore, when the effect of vitamin D supplementation on 
maternal 25(OH)D status was explored by season of birth, the decline in 25(OH)D from 14 
to 34 weeks’  gestation observed in placebo group women who delivered in winter and spring 
was not evident in the women, delivering in these same months, who received the vitamin D 
supplement (Figure 3). Frequency of non-protocol vitamin D containing supplement use did 
not vary by treatment group or season (Supplementary Table 7) and there was no effect of 
treatment on maternal adiposity (weight or skinfold thicknesses) at 34 weeks regardless of 
season (Supplementary Table 8).
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Safety analysis
Supplementary Table 9 documents the absolute numbers and percentages of adverse events 
by treatment group. Other than a greater proportion of women in the placebo group who had 
a report of severe postpartum haemorrhage, there were no differences in these safety 
measures.
DISCUSSION
Overall, we observed no effect of maternal supplementation with 1000IU/day cholecalciferol 
during pregnancy on the primary outcome (offspring neonatal bone mineral content). 
However the intervention clearly achieved maintenance of vitamin D repletion, and was safe. 
Furthermore, in a pre-specified secondary analysis we demonstrated an interaction between 
treatment and season of birth such that, for births in winter months, neonatal BMC, BA, 
BMD and body fat, but not birth weight or birth length, were greater amongst offspring of 
treatment versus placebo mothers. To our knowledge, this is the first published randomised 
controlled trial of vitamin D supplementation in pregnancy to include objective measures of 
offspring neonatal bone mass by DXA.
We undertook a large, population-based, double-blind, placebo-controlled, randomised trial, 
with standardised measures of vitamin D biochemistry and bone indices. However, there are 
some limitations that must be considered. First, we could not, as a result of stipulations 
made during the ethics approval process, include participants with 25(OH)D 
concentrations<25nmol/l. In addition, our study population did not include many members 
of ethnic minorities. If anything, both of these considerations are likely to bias towards the 
null hypothesis, but may reduce the generalisability of our findings. Second, DXA 
assessment in neonates presents some difficulties, as newborn babies are prone to move and 
have low absolute BMC. Appropriate software was used on each DXA instrument and DXA 
indices were cross-calibrated; the validity of the technique in small animals has been 
documented.30 Third, whilst we could not exclude the possibility that some participants 
were taking vitamin D additional to the study medication, supplement use was recorded and 
did not differ between the groups. Fourth, although the secondary analyses were pre-
specified, and that the interaction with season is consistent with previous literature and is 
biologically plausible, the possibility of false positive results remains. This finding should 
therefore be interpreted with caution pending replication in other populations.
We identified only one previously published intervention study in which neonatal bone 
outcomes were measured,31 although its null result is difficult to interpret given its small 
size (n=64) and methodological limitations.7 Following the demonstration, by Javaid et al,6 
of lower whole body BA, BMC and BMD, but not height or weight, at 9 years of age, in 
children born to mothers with 25(OH)D<25nmol/l in late pregnancy compared with those of 
replete mothers, other observational studies have documented positive associations between 
25(OH)D status in pregnancy and newborn bone indices assessed by DXA,32,33 pQCT at 
birth4 and 18 months,5 and ultrasound measures of fetal femoral morphology.2,3 The 
persistence of such associations into adulthood has been recently demonstrated in the 
Western Australian Pregnancy Cohort (RAINE).8 In contrast, four other studies15,34-36 
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found no association between maternal 25(OH)D and infant bone mass, highlighting the 
need for this randomised controlled trial.
Variation of 25(OH)D with season has been well documented19,27-29 and was also observed 
in this cohort (Supplementary Figure 4). UVB exposure to the skin is a major determinant of 
circulating 25(OH)D concentrations in temperate climates such as the UK, and since 
25(OH)D has a half life of around 3 weeks, the nadir appears in late winter/ early 
spring.37,38 In the present study, we observed a distinct fall in 25(OH)D concentration from 
14 to 34 weeks of pregnancy in the placebo group, but a rise in the treatment group, when 
delivery occurred during this period. Indeed, there was a statistically significant effect of 
treatment on neonatal BA, BMC and BMD for births between December and February, 
consistent with relationships observed between maternal gestational UVB exposure and 
infant bone mass in our previous cohort study.6 Although fat mass was greater in neonates 
born in winter months to mothers in the treatment versus placebo groups, there was no 
evidence of a treatment-by-season interaction for birth length or birth weight; a treatment-
by-season effect was apparent for BMC adjusted for birth length, suggesting that there is a 
specific influence on bone development rather than simply a generalised effect on birth size.
The majority of calcium mineral is accrued during the last trimester of pregnancy1, and our 
previous work has suggested that maternal factors (e.g. adiposity, physical activity, smoking, 
25(OH)D status) within the last trimester are associated with offspring bone mineral content, 
in contrast to exposures in early pregnancy, where associations tend to be much weaker1. 
Furthermore data from the Southampton Women’ s Survey demonstrate a seasonal difference 
in neonatal whole body BMC by season of birth, with winter births having lower BMC than 
summer births.39 It is therefore likely that low 25(OH)D is most important during the period 
of rapid bone mineral accrual in late pregnancy, consistent with effects of supplementation 
being observed where delivery is in the months of lowest 25(OH)D concentration. We 
therefore hypothesise that vitamin D supplementation, which reverses the drop in maternal 
25(OH)D concentrations from 14 to 34 weeks in spring, and particularly winter births, 
therefore ameliorates the adverse effect of this decline on offspring bone mineral content, 
with the overall effect being one of removal of deficit rather than overall improvement. 
However, conversely, we did not find a statistically significant effect of treatment amongst 
spring births, which would have been expected from the timing of the 25(OH)D nadir. Given 
the relatively arbitrary nature of seasonal definition in relation to objectively measured UVB 
exposure, we feel that the best reconciliation of the findings relating to late pregnancy 
25(OH)D in spring/winter with those relating to offspring bone in these seasons is that the 
supplement has the greatest effect in participants with an absolute decline in 25(OH)D above 
a notional threshold. Overall, these findings should be interpreted with caution, and 
replication of the treatment by season interaction in further studies will be required to 
delineate any messages for clinical care. The ongoing MAVIDOS childhood follow-up may 
also help to clarify this issue.
Notwithstanding, our findings inform public health policy, providing the first data from a 
large, blinded, randomised controlled trial with bone outcomes assessed by DXA, and 
demonstrating that overall, gestational supplementation with 1000 IU/day vitamin D does 
not benefit offspring neonatal bone mass. The intervention appeared safe, and although 
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vitamin D supplementation appeared to be associated with a reduced incidence of severe 
postpartum haemorrhage, we suspect that this is a false positive finding as a result of 
misclassification, since these events were not adjudicated and it is very difficult to accurately 
assess postpartum blood loss in the typical clinical situation. This finding will therefore 
remain the subject of further investigation. Although BMD was lower in treatment than 
placebo births occurring during the autumn, this was not statistically significant (p=0.07) 
and such differences were not consistent across other DXA indices. Finally, although the 
dose used in our study is 2.5 times the standard UK recommendation of 400 IU daily in 
pregnancy, it is much lower than the highest doses used in several US studies (up to 4000 IU 
daily)7 and our results clearly demonstrate that such high doses are not required in order to 
achieve good levels of 25(OH)D repletion.
In conclusion, we found that supplementation of pregnant women with 1000 IU/day 
cholecalciferol from 14 weeks gestation until delivery of the baby does not lead to increased 
offspring neonatal BMC overall. Our demonstration of an interaction between treatment and 
season of delivery is consistent with previous data and biologically plausible, but should be 
replicated in further populations before its significance for public health can be fully 
appreciated. The overall safety of vitamin D supplementation during pregnancy is supported 
by our results.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in context
Evidence before this study
We conducted a systematic review of studies relating maternal vitamin 25(OH)-vitamin D 
concentrations, UVB exposure, dietary vitamin D intake, or use of vitamin D 
supplements during pregnancy to maternal and offspring health outcomes.1 Major 
electronic databases (including, but not limited to, PubMed, Embase, Web of Science) 
were searched from their inception until June 2012. This was complemented by 
interrogation of grey literature and hand searching of reference lists. Two independent 
reviewers undertook all assessments, and the study was performed in accordance with 
PRISMA guidelines. We identified eight observational studies relating maternal 
gestational vitamin D status to offspring bone mass, all of which were assessed as being 
of medium to low risk of bias. Of these, five demonstrated a significant positive 
relationship between maternal vitamin D status and offspring bone outcomes2-6 [which 
included whole body, lumbar, femoral and tibial bone mineral content (BMC), and whole 
body and lumbar spine bone mineral density (BMD)]. Of the remaining studies, no 
significant association was observed between maternal vitamin D status and offspring 
radial and whole body BMC.7-9 Differences in study design did not permit meta-analysis. 
We identified one small intervention study,10 judged to be at high risk of bias, which 
found no difference in offspring forearm BMC (measured within five days of birth) 
between supplemented and un-supplemented mothers. We subsequently updated the 
search to August 2014, identifying two further observational studies, both judged to be 
low to medium risk of bias: one, using the ALSPAC cohort, demonstrated no association 
between maternal 25(OH)-vitamin D concentrations in pregnancy and offspring bone 
mass at 9 years.11 In contrast, the second study, from the Australian Raine cohort, 
documented positive relationships between maternal gestational 25(OH)-vitamin D 
concentrations offspring bone mass at 20 years.12
Added value of this study
There was no difference in the primary outcome (neonatal whole body BMC) between 
offspring born to mothers supplemented with vitamin D during pregnancy compared with 
mothers randomised to placebo. However, amongst the pre-specified secondary analyses, 
there was an interaction between treatment and season, with the suggestion of a benefit 
for offspring neonatal bone mineral content with treatment for deliveries during winter 
months. Although biologically plausible, this intriguing finding clearly requires 
replication in further studies before it can provide a basis for alterations to clinical care.
Implications of all the available evidence
Vitamin D supplementation during pregnancy is already recommended in many 
countries, including the UK. Observational studies have provided conflicting evidence 
regarding associations between maternal 25(OH)-vitamin D status and offspring 
intrauterine bone development. The MAVIDOS study, whilst negative for its primary 
outcome, has demonstrated that 1000 IU cholecalciferol daily is sufficient to ensure the 
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majority of pregnant women are replete in 25(OH)-vitamin D, and that such a strategy is 
safe.
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Figure 1. 
Consort diagram
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Figure 2. 
Neonatal whole body a) bone area, b) bone mineral content and c) bone mineral density by 
intervention group and season of birth. [Winter = December to February]. Data shown are 
mean and 95%CI.
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Figure 3. 
Maternal 25(OH)D status at baseline (14 weeks gestation) and 34 weeks’  gestation by 
randomisation to either 1000IU/day cholecalciferol or placebo and season of birth. [Winter = 
December to February]. Data shown are mean and 95%CI.
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Table 1
Baseline maternal characteristics by randomisation group
Placebo Cholecalciferol (1000 IU/day)
N 569 565
Age (years), mean±SD 30.5 ± 5.2 30.5 ± 5.2
Ethnicity, % Caucasian 94.3 94
Parity, % nulliparous 43.9 43.6
Current smoker, % 8.2 8.3
Educational attainment ≥ A level, % 75.3 78.0
Walking speed at least fairly brisk, % 41.0 38.2
Strenuous exercise ≥ once week, % 14.0 15.7
Height (cm), mean±SD 165.8 ± 6.6 165.6 ± 6.4
Weight (kg), median (IQR) 71.4 (63.3-81.8) 68.4 (60.9-79.5)
BMI (kg/m2), median (IQR) 25.7 (23.0-30.0) 24.7 (22.3-28.6)
Sum of all skinfold (mm), mean±SD 84.0 ± 27.8 79.8 ± 27.9
25(OH)D (nmol/l), mean±SD 45.9 ± 17.0 46.7 ± 17.7
25(OH)D>50nmol/l, % 37.3 40.8
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Table 2
Anthropometry, whole body bone mineralisation and body composition in neonates born to mothers 
randomised to 1000 IU/day cholecalciferol or placebo from 14 weeks’  gestation until delivery. Data displayed 
as mean±SD, unless otherwise stated
Placebo Cholecalciferol (1000 IU/day) p
Obstetric data
N 486 479
Male, N (%) 251 (51.7) 258 (53.9) 0.49
Birth weight (g) 3518 ± 517 3481 ± 543 0.28
Crown-heel length (cm) 50.8 ± 2.3 50.6 ± 2.6 0.31
Head circumference (cm) 35.5 ± 1.5 35.4 ± 1.4 0.62
Abdominal circumference (cm) 32.7 ± 2.3 32.9 ± 2.2 0.16
DXA
Whole body
N 327 338
Age at DXA (days) 7 ± 6 8 ± 7 0.12
Bone Area (cm2) 297.8 ± 37.3 301.6 ± 34.7 0.18
BMC (g) 60.5 ± 11.1 61.6 ± 11.7 0.21
BMD (g/cm2) 0.203 ± 0.019 0.203 ±0.022 0.96
Lean (g) 3014 ± 435 3055 ± 423 0.23
Fat (g), median (IQR) 374 (244-517) 355 (235-564) 0.97
Lancet Diabetes Endocrinol. Author manuscript; available in PMC 2016 November 01.
